Formycon Shifts Strategy On US Lucentis Biosimilar

As First Patient Dosed In Ustekinumab Phase III Studies

 
• By Dean Rudge
  
Sand running through the bulbs of an hourglass measuring the passing time in a countdown to a deadline, on a dark background with copy space.
The required pre-filing meetings with FDA are now expected to take place in early 2021 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products